Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
It is the first autotaxin inhibitor to be investigated in cancer patients
These approvals mark significant progress for Venus Remedies in expanding its market presence
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
These regulatory approvals signify a significant milestone for Venus Remedies Limited
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
For the treatment of Superficial Femoral Artery
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)